During the past decade, Synexus Watermeyer Clinical Research Centre conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 7 clinical trials were completed, i.e. on average, 116.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Synexus Watermeyer Clinical Research Centre" #1 sponsor was "Pfizer" with 3 trials, followed by "Janssen Vaccines & Prevention B.V." with 2 trials sponsored, "Biota Scientific Management Pty Ltd" with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored and "Kowa Research Institute, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Synexus Watermeyer Clinical Research Centre" #1 collaborator was "Bio Analytical Research Corporation" with 1 trials as a collaborator, "BioVac" with 1 trials as a collaborator, "Biocair" with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator and "Clinical Laboratory Services" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Synexus Watermeyer Clinical Research Centre" are "Cardiovascular Disease" (2 trials), "Depressive Disorder, Major" (1 trials), "Dyslipidemia" (1 trials), "Heterozygous Familial Hypercholesterolemia" (1 trials) and "Influenza" (1 trials). Many other conditions were trialed in "Synexus Watermeyer Clinical Research Centre" in a lesser frequency.

Most popular intervention types in "Synexus Watermeyer Clinical Research Centre" are "Drug" (8 trials), "Biological" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "bococizumab (PF-04950615)" (2 trials), "40 mg Laninamivir Octanoate" (1 trials), "80 mg Laninamivir Octanoate" (1 trials) and "Ad26.COV2.S" (1 trials). Other intervention names were less common.

The vast majority of trials in "Synexus Watermeyer Clinical Research Centre" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Synexus Watermeyer Clinical Research Centre". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Synexus Watermeyer Clinical Research Centre, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Synexus Watermeyer Clinical Research Centre, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".